Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

RIDGEFIELD, Conn., Oct. 22, 2018 /PRNewswire/ -- Boehringer Ingelheim today announced results from GioTag, a real-world retrospective, observational study, which assessed total treatment duration of first-line Gilotrif® (afatinib) followed by......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Monday, 22 October

Share |